Journal of Clinical Oncology最新文献

{"title":"Closing the Gap: Evaluating Medicare's Low-Income Subsidy Support for Optimal Cancer Care.","authors":"S M Qasim Hussaini, Gabrielle B Rocque","doi":"10.1200/JCO-24-02197","DOIUrl":"10.1200/JCO-24-02197","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"484-486"},"PeriodicalIF":42.1,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11798711/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.","authors":"John F R Robertson, Zhimin Shao, Shinzaburo Noguchi, Igor Bondarenko, Lawrence Panasci, Sandeep Singh, Shankar Subramaniam, Matthew J Ellis","doi":"10.1200/JCO-25-00116","DOIUrl":"https://doi.org/10.1200/JCO-25-00116","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2500116"},"PeriodicalIF":42.1,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143370817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary.","authors":"Sapna P Patel, Rahul A Sheth, Christina Davis, Theresa Medina","doi":"10.1200/JCO-24-01802","DOIUrl":"https://doi.org/10.1200/JCO-24-01802","url":null,"abstract":"<p><p><i>The</i> Oncology Grand Rounds <i>series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in</i> Journal of Clinical Oncology<i>, to patients seen in their own clinical practice</i>.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2401802"},"PeriodicalIF":42.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Missed Opportunity for Sotorasib Dose Optimization.","authors":"Garth W Strohbehn, Jill Feldman, Sanjay Popat, Mark J Ratain","doi":"10.1200/JCO-24-02468","DOIUrl":"https://doi.org/10.1200/JCO-24-02468","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2402468"},"PeriodicalIF":42.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Making Progress Along the Challenging Road of Drug Development for Patients With <i>EGFR</i> Exon 20 Insertion-Positive Non-Small Cell Lung Cancer.","authors":"Zofia Piotrowska","doi":"10.1200/JCO-24-02656","DOIUrl":"https://doi.org/10.1200/JCO-24-02656","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2402656"},"PeriodicalIF":42.1,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rethinking the Path to Bladder Cancer Staging: Can Magnetic Resonance Imaging Speed Up Time to Receipt of Therapy in Patients With Muscle-Invasive Bladder Cancer?","authors":"Ashish M Kamat, Paul Frankel","doi":"10.1200/JCO-24-02482","DOIUrl":"https://doi.org/10.1200/JCO-24-02482","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2402482"},"PeriodicalIF":42.1,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece Trials.","authors":"Julien Taieb, John Souglakos, Ioannis Boukovinas, Antoine Falcoz, Franck Pages, Ippokratis Messaritakis, Jaafar Bennouna, Pascal Artru, Christophe Louvet, Celine Lepere, Jean Francois Emile, Olivier Bouche, Thibault Mazard, Dewi Vernerey, Konstantinos Vogiatzoglou, Maria Tzardi, Shruti Sharma, Minetta C Liu, Himanshu Sethi, Thierry André, Jérome Galon, Pierre Laurent-Puig","doi":"10.1200/JCO.24.00648","DOIUrl":"https://doi.org/10.1200/JCO.24.00648","url":null,"abstract":"<p><strong>Purpose: </strong>Immunoscore (IS) and circulating tumor DNA (ctDNA) are two emerging technologies in improving prognostication and tailoring adjuvant treatments in patients resected from a stage III colon cancer (CC). Here, we analyzed the prognostic value of the two biomarkers in patients who participated in the randomized phase III IDEA-France and HORG trials.</p><p><strong>Methods: </strong>Plasma samples were collected after surgery and before adjuvant chemotherapy. ctDNA analysis was performed using a clinically validated, personalized, tumor-informed 16-plex protein chain reaction assay. Multivariable analyses for time to recurrence (TTR; patients without recurrence or death due to CC) and overall survival (OS) were performed using ctDNA and IS results, along with other parameters including treatment duration and disease risk group.</p><p><strong>Results: </strong>Of the 554 patients with available ctDNA results, 445 were ctDNA-negative (80.3%) and 109 were ctDNA-positive (19.7%); baseline characteristics showed more T4/N2 and venous embolism/lymphatic invasion/perineural invasion+ in ctDNA-positive patients. With a median follow-up of 6.7 years, the 2-year TTR rate was 43.5% (95% CI, 34.1 to 52.6) for ctDNA-positive patients and 88.1% (95% CI, 84.7 to 90.8) for ctDNA-negative patients (<i>P</i> < .0001). ctDNA was confirmed as an independent prognostic marker for both TTR (adjusted hazard ratio [adjHR], 5.21 [95% CI, 3.59 to 7.58]; <i>P</i> < .001) and OS (adjHR, 4.84 [95% CI, 3.40 to 6.89]; <i>P</i> < .001). ctDNA remained the most significant prognostic factor irrespective of disease stage, treatment duration, and IS results. IS was not prognostic in ctDNA-positive patients but remained a significant prognostic tool for ctDNA-negative patients.</p><p><strong>Conclusion: </strong>In this combined analysis of two adjuvant trials dedicated to patients with stage III CC after surgery, ctDNA was detectable in 19.7% of the patients and was confirmed as a major independent prognostic biomarker. IS seems to bring additional prognostic information in the 80.3% of patients who are ctDNA-negative.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2400648"},"PeriodicalIF":42.1,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.","authors":"Sebastian Stintzing, Susanne Klein-Scory, Ludwig Fischer von Weikersthal, Martin Fuchs, Florian Kaiser, Kathrin Heinrich, Dominik Paul Modest, Ralf-Dieter Hofheinz, Thomas Decker, Armin Gerger, Stefan Angermeier, Holger Rumpold, Andreas Dickhut, Leopold Öhler, Birgit Gruenberger, Dora Niedersuess-Beke, Matthias Sandmann, Thomas Winder, Joerg Trojan, Gerald Prager, Swantje Held, Jörg Kumbrink, Wolff Schmiegel, Alexander Baraniskin, Volker Heinemann","doi":"10.1200/JCO.24.01174","DOIUrl":"https://doi.org/10.1200/JCO.24.01174","url":null,"abstract":"<p><strong>Purpose: </strong>The FIRE-4 study randomly assigned patients with first-line <i>RAS</i> wild-type (<i>RAS</i>wt) metastatic colorectal cancer to either flourouracil (FU), folinic acid, and irinotecan (FOLFIRI) plus cetuximab until progression or intolerable toxicity (standard arm) or to FOLFIRI plus cetuximab followed by a switch maintenance treatment using FU plus bevacizumab (experimental arm). Here, we investigate the relevance of liquid biopsy (LB) RAS and BRAF testing compared with tissue-based analyses.</p><p><strong>Patients and methods: </strong>LBs were taken at baseline and during treatment and were analyzed for <i>RAS</i> and <i>BRAF</i>^V600E mutations using the in vitro diagnostics-certified ONCOBEAM RAS procedure (Sysmex Inostics) and digital-droplet polymerase chain reaction technology.</p><p><strong>Results: </strong>Six hundred seventy-two <i>RAS</i>wt patients were randomly assigned. LBs of 540 patients were evaluable at baseline. Of those, 70 (13%) were <i>RAS</i> mutant (<i>RAS</i>mut) and 38 (7%) <i>BRAF</i>^V600E mutant. <i>RAS</i>mut patients had significantly shorter survival compared with <i>RAS</i>wt patients (progression-free survival [PFS], 9.0 months <i>v</i> 11.5 months; <i>P</i> < .001; hazard ratio [HR], 1.66; overall survival [OS], 22.1 months <i>v</i> 33.6 months; <i>P</i> < .001; HR, 1.85). <i>RAS</i>mut patients had a numerically greater benefit from early switch maintenance compared with continuation of FOLFIRI/cetuximab (PFS, 10.1 months <i>v</i> 6.4 months; HR, 0.82; OS, 24.9 months <i>v</i> 16.3 months; HR, 0.57). Patients with a <i>BRAF</i>^V600E mutation in LB showed poor outcome (PFS, 5.4 months; OS, 12.0 months). On the basis of serial LB analyses, the conversion rate from <i>RAS</i>wt to <i>RAS</i>mut at disease progression was significantly higher in the arm with continuous cetuximab administration than in the switch maintenance arm.</p><p><strong>Conclusion: </strong>LB allows the detection of <i>RAS</i> and <i>BRAF</i> mutations in patients deemed <i>RAS</i>wt on the basis of tissue analyses. These patients show outcome characteristics expected for <i>RAS</i>- and <i>BRAF</i>-mutant patients in tissue. The study thus confirms the high clinical relevance of LB performed at baseline before the start of therapy.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2401174"},"PeriodicalIF":42.1,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aiming Targeted Drug Development at Rare Pediatric Malignancies.","authors":"Julia L Glade Bender","doi":"10.1200/JCO-25-00009","DOIUrl":"https://doi.org/10.1200/JCO-25-00009","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2500009"},"PeriodicalIF":42.1,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anthracyclines in Early Breast Cancer: The Long Goodbye.","authors":"Thomas Grinda, Harold J Burstein","doi":"10.1200/JCO-24-01916","DOIUrl":"10.1200/JCO-24-01916","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"361-364"},"PeriodicalIF":42.1,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}